IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 1 of 93  
CLINICAL STUDY PROTOCOL  
 
 
A Randomized, Double- Blind, Placebo -Controlled, Ascending Dose Cohort 
Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB -001 in 
Subjects with Glabellar Frown Lines  
 
Study Number:  EB001 -GL201 
 
IN
D Sponsor : Bonti, Inc. 
 
 
Version Number:   2.0 
Amendment:     1 
Revised Final  Date :  18 November 2016  
Original Protocol Date : [ADDRESS_1007035] be 
informed that th e information is confidential and may not be further disclosed by [CONTACT_476]. 
These restrictions on disclosure will apply equally to all future information supplied to you which is indicated as confidential.  

IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 2 of 93 

IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 3 of 93 SIGNATURE [CONTACT_737210]:  
 

[CONTACT_116909] 130880  18 November  2016 
 
 Confidential / Trade Secret  Page [ADDRESS_1007036] read this protocol and agree  
• to assume responsib ility for the proper conduct of the study at this site , 
• to conduct the study according to the procedures described in this protocol and any future amendments ,  
• not to implement any deviation from, or changes to, the protocol without agreement of the sponso r and written approval from the Institutional Review Board 
or Independent Ethics Committee, except where necessary to eliminate an 
immediate hazard to subject(s) , and  
• that I am aware of and will comply with all applicable regulations and guidelines  
 
  _______________________   _______________________   ____________________  
 Investigator  Printed Name  [CONTACT_32510]  
   _______________________   _______________________   ____________________  
 Investigator  Printed Name  [CONTACT_737211] 130880  18 November  2016 
 
 Confidential / Trade Secret  Page [ADDRESS_1007037] OF ABBREVIATIONS AND GLOSSARY OF TERMS ............................................................... 11 
PROTOCOL SUMMARY  ............................................................................................................. 14 
1 KEY ROLES  .......................................................................................................................... 24 
2 INTRODUCTION  .................................................................................................................. 25 
2.1 Background Information  ................................................................................................ 25 
2.1.1  Overview of Botulinum Neurotoxins  ......................................................................... 25 
2.1.2  Human Experience of EB -001 .................................................................................... 25 
2.1.3  Chemistry  ................................................................................................................... 26 
2.1.4  Nonclinical Evaluation of EB -001 ............................................................................... 26 
[IP_ADDRESS]  Toxicology ............................................................................................................... 26 
[IP_ADDRESS]  Nonclinical Risk Assessment of EB -001 .................................................................. 27 
[IP_ADDRESS]  in vivo  Studies  ........................................................................................................ 28 
2.2 Rationale  ........................................................................................................................ 28 
2.2.1  Study Rationale  .......................................................................................................... 28 
2.2.2  Dose Selection Rationale  ........................................................................................... 28 
2.3 Potential Risks and Benefits  .......................................................................................... 29 
2.3.1  Known Potential Risks  ............................................................................................... 29 
2.3.2  Known Potential Ben efits  .......................................................................................... 31 
3 OBJECTIVES AND PURPOSE  ................................................................................................ 32 
4 STUDY DESIGN AND ENDPOINTS  ....................................................................................... 33 
4.1 Description of the Study Design  .................................................................................... 33 
4.1.1  Stoppi[INVESTIGATOR_2121]  ........................................................................................................ 35 
4.1.2  Follow -up of Subjects Meeting Stoppi[INVESTIGATOR_2121]  ...................................................... 36 
4.2 Study Endpoints  ............................................................................................................. 36 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 6 of 93 4.2.1  Safety Endpoints  ........................................................................................................ 36 
4.2.2  Primary E fficacy Endpoint  .......................................................................................... 37 
4.2.3  Secondary Efficacy Endpoints  .................................................................................... 37 
5 STUDY ENROLLMENT AND WITHDRAWAL  ......................................................................... 38 
5.1 Participant Inclusion Criteria  ......................................................................................... 38 
5.2 Participant Exclusion Criteria  ......................................................................................... 39 
5.3 Strategies for Re cruitment and Retention  ..................................................................... 40 
5.4 Participant Withdrawal or Termination  ......................................................................... 40 
5.4.1  Reasons for Withdrawal or Termination  ................................................................... 40 
5.4.2  Handling of Participant Withdrawals or Termination  ............................................... 41 
5.5 Premature Termination or Suspension of Study  ........................................................... 41 
6 STUDY AGENT  .................................................................................................................... 42 
6.1 Study Agent(s) and Control Description  ........................................................................ [ADDRESS_1007038] Storage  ......................................................................................................... 42 
6.1.4  Preparation  ................................................................................................................ 42 
6.1.5  Dosing and Administration ........................................................................................ 43 
6.1.6  Route of Administration  ............................................................................................ 43 
6.1.7  Starting Dose and Dose Escalation Schedule  ............................................................ 43 
6.1.8  Dose Adjustments/Modification/Delays  ................................................................... [ADDRESS_1007039] Accountability Procedures  ....................................................... 44 
7 STUDY PROCEDURES AND SCHEDULE ................................................................................ 45 
7.1 Study Procedures/Evaluations  ....................................................................................... 45 
7.1.1  Study Specific Procedures  ......................................................................................... 45 
[IP_ADDRESS]  Informed Consent  .................................................................................................. 46 
[IP_ADDRESS]  Demographics  ........................................................................................................ 46 
[IP_ADDRESS]  Assessment of Inclusion/Exclusion Criteria  ........................................................... 46 
[IP_ADDRESS]  Medical History  ...................................................................................................... 46 
[IP_ADDRESS]  Assessment of Adverse Event  ................................................................................ 46 
[IP_ADDRESS]  Height and Weight .................................................................................................  46 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 7 of 93 [IP_ADDRESS]  Complete Physical and Focused Neurological Examinations  .................................  46 
[IP_ADDRESS]  Mini Physical and Focused Neurological Examinations  ......................................... 47 
[IP_ADDRESS]  Prior and Concomitant Medications  ...................................................................... 47 
[IP_ADDRESS]  12-Lead ECG  ........................................................................................................... 47 
[IP_ADDRESS]  Body Temperature, Respi[INVESTIGATOR_26452], Blood Pressure, and Pulse Rate  ................. 47 
[IP_ADDRESS]  Serum Chemistry, Lipi[INVESTIGATOR_805], Hematology  ................................................................... 48 
[IP_ADDRESS]  Urinalysis  ................................................................................................................ 48 
[IP_ADDRESS]  Immunogenicity Sample Collection  ....................................................................... 48 
[IP_ADDRESS]  Screens for HIV and Hepatitis B  and C  ................................................................... 48 
[IP_ADDRESS]  Screens for Alcohol / Drugs of Abuse  .................................................................... 49 
[IP_ADDRESS]  Pregnancy Test  ....................................................................................................... 49 
[IP_ADDRESS]  Study Drug Administration .................................................................................... 49 
[IP_ADDRESS]  Standardized Facial Photography  ........................................................................... 49 
[IP_ADDRESS]  Facial Wrinkle Scale – Subject Assessment  ............................................................ 50 
[IP_ADDRESS]  Facial Wrinkle Scale – Investigator Assessment  ..................................................... 50 
7.2 Laboratory Procedures/Evaluations  .............................................................................. 50 
7.2.1  Clinical Laboratory Evaluations  .................................................................................. 50 
7.2.2  Specimen Preparation, Handling, and Storage  .......................................................... 50 
7.2.3  Specimen Shipment  ................................................................................................... 50 
7.2.4  Volume of Blood Collected  ........................................................................................ 50 
7.3 Study Schedule  .............................................................................................................. 51 
7.3.1  Screening Visit (Days - 30 to - 1) ................................................................................. 51 
7.3.2  Baseline Visit (Day 0)  .................................................................................................  51 
7.3.3 Follow -Up Visits (Days 1, 2, 7, AND 14)  ..................................................................... 51 
7.3.4  End of Study (Day 30) / Early Termination Visit  ........................................................ [ADDRESS_1007040] ion ......................................................................................................... 55 
8 ASSESSMENT OF SAFETY  .................................................................................................... 57 
8.1 Specification of Safety Parameters  ................................................................................ 57 
8.1.1  Definition of Adverse Events (AE)  .............................................................................. 57 
8.1.2  Definition of Serious Adverse Events (SAE)  ............................................................... 58 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 8 of 93 [IP_ADDRESS]  Elective Proce dures, and Surgeries  ........................................................................ 59 
8.1.3  Definition of Unanticipated Problems (UP)  ............................................................... 59 
8.2 Classification of an Adverse Event  ................................................................................. 60 
8.2.1  Severity of Event  ........................................................................................................ 60 
8.2.2  Relationship to Study Agent  ...................................................................................... 60 
8.2.3  Expec tedness  ............................................................................................................. 61 
8.3 Time Period and Frequency for Event Assessment and Follow -up ............................... 61 
8.4 Reporting Procedures  .................................................................................................... 62 
8.5 Adverse Event Reporting  ............................................................................................... 62 
8.5.1  Serious Adverse Event Reporting  .............................................................................. 63 
8.5.2  Reporti ng of Pregnancy  ............................................................................................. 64 
8.6 Study Halting Rules  ........................................................................................................ 65 
8.7 Safety Oversight  ............................................................................................................. 65 
9 CLINICAL MONITORING AND COMPLIANCE  ...................................................................... 66 
10 STATISTICAL CONSIDERATIONS  .......................................................................................... 67 
10.1  Statistical and Analytical Plans  ...................................................................................... 67 
10.2  Statistical Hypotheses  .................................................................................................... 67 
10.3  Analysis Datasets  ........................................................................................................... 67 
10.4  Descriptio n of Statistical Methods  ................................................................................ 67 
10.4.1  General Approach  ...................................................................................................... 67 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 67 
10.4.3  Analysis of the Secondary Endpoint(s)  ...................................................................... 68 
10.4.4  Safety Analyses  .......................................................................................................... 68 
[IP_ADDRESS]  Demographics and Baseline Characteristics  .......................................................... 68 
[IP_ADDRESS]  Prior and Concomitant Medications  ...................................................................... 68 
[IP_ADDRESS]  Completion of the Study and Withdrawals  ........................................................... 68 
[IP_ADDRESS]  Tolerability Analysis  ............................................................................................... 68 
[IP_ADDRESS]  Adverse Events  ....................................................................................................... 68 
[IP_ADDRESS]  Clinical Laboratory Tests  ........................................................................................ 69 
[IP_ADDRESS]  Vital Signs ............................................................................................................... 69 
[IP_ADDRESS]  Electrocardiograms  ................................................................................................ 70 
[IP_ADDRESS]  Physical and Focused Neurological Examinations  ................................................. 70 
[IP_ADDRESS]  Immunogenicity  ..................................................................................................... 71 
[IP_ADDRESS]  Urine Drug Test  ...................................................................................................... 71 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 9 of 93 [IP_ADDRESS]  Pregnancy Test  ....................................................................................................... 71 
10.4.5  Planned Interim Analyses  .......................................................................................... 71 
10.4.6  Exploratory Analyses  .................................................................................................  71 
10.5  Sample Size  .................................................................................................................... 71 
10.6  Measures to Minimize Bias  ............................................................................................ 72 
10.6.1  Enrollment/ Randomization/ Blinding Procedures  .................................................... 72 
[IP_ADDRESS]  Subject Numbering  ................................................................................................ 72 
10.6.2  Evaluation of Success of Blinding  .............................................................................. 73 
[IP_ADDRESS]  Blinding at the Study Site  ....................................................................................... 73 
[IP_ADDRESS]  Blinding of Sponsor Personnel  ............................................................................... 73 
10.6.3  Breaking the Study Blind/Participant Code  ............................................................... 73 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .............................. 75 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .................................................................  76 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ..................................................................... [ADDRESS_1007041] POLICY  ......................................................................................... 82 
16 LITERATURE REFERENCES  .................................................................................................. 83 
17 APPENDIX  ........................................................................................................................... 85 
 
 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page [ADDRESS_1007042]  .................................................................................... 93 
 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page [ADDRESS_1007043] OF ABBREVIATIONS  AND GLOSSARY OF TERMS  
Term  Definition  
AE adverse event  
ALT (SGPT)  alanine aminotransferase (=  serum glutamic pyruvic transaminase)  
AST (SGOT)  aspartate aminotransferase (= s erum glutamic oxaloacetic 
transaminase)  
BoNT  botulinum neurotoxin  
BoNT /A botulinum neurotoxin  serotype A  
BoNT/E  botulinum neurotoxin serotype E  
BP blood pressure  
BUN  blood urea nitrogen  
CBL change from baseline  
CFR Code of Federal Regulations  
CMP  clinical monitoring plan 
CRF Case Report Form 
CRO  Contract Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
DAS digital abduction score  
DRT Data Review Team  
EB-[ADDRESS_1007044]  50% DAS effect  
EDC electronic data capture  
EOS end o f study  
ET early termination  
F-U follow up 
FDA Food and Drug Administration  
FIH first-in-human  
FWS  facial wrinkle scale 
GCP Good Clinical Practice  
GGT  γ glutamyl transferase  
GL glabellar frown Lines  
GLP Good Laboratory Practices  
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 12 of 93 Term  Definition  
GMP  Good Manufacturing Practices  
HBsAg  hepatitis B s urface antigen  
HC heavy chain  
HDL high density lipoprotein  
HED  human equivalent dose 
HEEN T head, eye, ear, nose, throat  
HIV human immunodeficiency virus 
HR heart rate  
HSA human serum albumin  
ICF informed consent form 
ICH International Conference on Harmonization  
ICH E6  International Conference on Harmonization Guidance for Industry, 
Good Clinical Practice: Consolidated Guidance  
IEC independent ethics committee  
IM intramuscular  
IRB institutional review board  
IVRS  interactive voice response system  
IWRS  interactive web response system  
LC light chain  
LDH lactate dehydrogenase  
LDL low density lipoprotein  
M molar  
MCH mean cell hemoglobin  
MCHC mean cell hemoglobin concentration  
MCV  mean ( red) cell volume  
MedDRA  Medical Dictionary for Regulatory Activities  
mL milliliter  
mouse LD50 lethal dose to 50% of mice after intraperitoneal in jection  
MRSD  maximum recommended starting dose  
msec  milliseconds  
NA not applicable  
ng nano gram  
NOAEL  no observable adverse effects limit 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 13 of 93 Term  Definition  
OHRP  Office for Human Research Protections  
PAD pharmacologically active dose 
PCV packed cell volume  
PI [INVESTIGATOR_737171]-needed  
RBC red blood cell 
RDW  red (cell) distribution width 
RR interval  time elapsed between two consecutive R -waves  
QRS duration  the interval from the beginning of the Q wave to the termination of the S wave, representing the time for ventricular depolarization  
QT interval  interval represent ing the time for both ventricular depolarization 
and repolarization to occur  
QTc corrected QT  (interval)  
QT
cB interval  QTc interval using Bazett’s correction (msec) = QT/(RR)½, where the 
QT interval is measured in msec and the RR interval is measured in 
seconds  
QT cF interval  QTc interval using Fridericia’s correction (msec) = QT/(RR)⅓, where 
the QT interval is measured in msec and the RR interval is measured in seconds  
SAE serious adverse event/ experience  
SAP statistical analysis plan 
SNAP  synaptosomal- associated protein 
SOT spread of t oxin 
S[LOCATION_003]R  suspected unexpected serious adver se reactions  
RR interval  time elapsing between two consecutive R waves in the 
electrocardiogram. It is used to assess the ventricular rate.  
TCA trichloroacetic Acid  
TEAE treatment emergent adverse event  
UP unanticipated problem  
US [LOCATION_002]  
WBC  white blood cell (Leukocyte)  
 
 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 14 of 93  PROTOCOL SUMMARY  
 
Study Number:  
EB001- GL201  
 
Study Title:  
A Randomized, Double -Blind, Placebo -Controlled, Ascending Dose Cohort Study to Evaluate 
Safety and Efficacy of a Single Treatment Cycle of EB -[ADDRESS_1007045]:  
EB-001 (Botulinum Neur otoxin Serotype E, BoNT/E) for i njection . 
 
Study Objectives:  
To evaluate the safety and efficacy of EB -001 compared to placebo in subjects with glabellar 
frown lines (GL).  
 
Phase of T rial: 
Phase 2a  
 
Clinical Hypothesis:  
Safety : A single treatment cycle of EB -001 Intramuscular (IM) injections into the glabellar 
muscles (procerus and bilateral corrugator muscles) has an acceptable safety, 
immunogenicity, and tolerability profile at the t ested dose range.   Immunogenicity  testing 
will be performed once methods have been developed.  
 
Efficacy : A single treatment cycle of EB -001 IM injections, at one or more of the tested 
doses, is more effective than placebo in the treatment of GL assessed u sing the Facial 
Wrinkle Scale (FWS).  
 
Study Population:  
Males and Females 18 -60 years old , with moderate to severe GL at maximum frown using 
the FWS . 
 
Outcome Measures:  
Safety Measures:  
• Incidence and severity of treatment emergent adverse events (TEAEs)  and serious 
adverse events (SAEs)  
• Focused neurologic examination  for potential spread of toxin  (SOT)  
• Incidence of abnormal findings in laboratory tests, electrocardiogram (ECG), physical 
exam, and vital signs (pulse rate, respi[INVESTIGATOR_697], and blood p ressure)  
• Pregnancy test for women of childbearing potential  
 
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 15 of 93 Efficacy Measures:  
Primary Efficacy Measures:  
• Investigator ’s assessment of GL severity at maximum frown using the FWS. The FWS 
is a four -point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = 
moderate, or 3 = severe.  
 
 
  
  
 
Study Design:  
This will be the first -in-human (FIH) , randomized, double -blind, placebo -controlled, 
ascending dose cohort study  of EB -001.   
 
A total of 7 ascending dose cohorts are planned for GL injections  or up to 9 cohorts if 2 
addi tional cohorts are evaluated . Each dose cohort will enroll a total of 6 subjects 
randomized to receive either EB -001 or placebo in a ratio of 5 (active): 1 (placebo).  
 
Duration:  
Expected duration is approximately [ADDRESS_1007046] from the day of study treatment to the follow -up visit, and approximately 10 weeks from signing ICF to the follow -
up exit.  
 
Inclusion Criteria:  
In order to be eligible to participate in this study, an individual must meet ALL of the 
following criteria: 
1. Signed and dated IRB -approved informed consent  form (ICF). 
2. Men or women between the ages of 18 and 60, inclusive.  
3. Subjects in good health as determined by [CONTACT_9870], physical and focused 
neurological  examination s, clinical laboratory studies, electrocardiograms (ECGs), 
vital signs, and Investigator’s  judgement . 
4. Presence of bilaterally symmetrical GL of moderate to severe rating at maximum frown, as measured using FWS by [CONTACT_737189].  
5. Subjects with  sufficient visual acuity wit hout the use of eyeglasses (contact [CONTACT_442248]) to accurately assess their facial wrinkles  as determined by [CONTACT_10670]’s 
judgement . 
6. Women of child bearing potential must not be pregnant, lactating, or planning to 
become pregnant during the study .  
7. Women of non -childbearing potential must be either postmenopausal  (at least 12 
consecutive months  of amenorrhea ) or surgically sterile (e.g., tubal ligation, 
hysterect omy, etc.).  

IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page [ADDRESS_1007047] 2  months prior to the day of 
dosing.   
9. Male subjects with partner(s) of childbearing potential agree ing to use dual metho ds 
of contraception from the day of dosing until 3  months afterwards, and to no sperm 
donation from day of dosing until 3  months afterwards.  
10. Willing and able to complete protocol requirements and instructions, which include 
completion of all required visit s. 
 
Exclu sion Criteria:  
An individual who meets ANY  of the following criteria will be excluded from participation in 
this study:  
1. Any condition that precludes a subject’s ability to comply with study requirements, 
including completion of the study visits or  inability to read, understand, and/or self -
assess GL severity using FWS.  
2. Any uncontrolled systemic disease or other medical condition.  
3. Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including diagnosed myasthenia gravis, Eaton -
Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.  
4. Current or previous botulinum toxin treatment of any serotype.  
5. Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment).  
6. Known immunization or hypersensitivity to any botulinum toxin serotype.  
7. Known allergy or sensitivity to any of the components of the study treatments, or any materials used in the study procedures.  
8. Any of the following procedures or treatments occurring with in the specified period 
prior to  screening : 
o 3 months: Non -ablative resurfacing laser or light treatment, microdermabrasion, 
or superficial peels.  
o 6 months:  Any facial cosmetic procedure with medium depth to deep facial 
chemical peels (e.g., trichloroacetic acid [TCA] and phenol), or mid facial or periorbital laser skin resurfacing.  
o 6 months: On topi[INVESTIGATOR_737172]/or topi[INVESTIGATOR_737173], who have not been on a co nsistent dose regimen and are unable to 
maintain  the same regimen for the study . 
o 12 months: Mid- facial or periorbital treatment with non -permanent soft tissue 
fillers.  
o 12 months: O n oral retinoid therapy.  
9. Prior periorbit al surgery, facial lift (full face or mid face), brow lift, or related 
procedures (e.g., eyelid [blepharoplasty] and/or eyebrow surgery).  
10. Prior mid face or periorbital treatment with permanent soft tissue fillers, synthetic implantation (e.g., Gore -Tex®), and/or autologous fat transplantation.  
IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 17 of 93 11. Marked facial asymmetry, dermatochalasis, deep dermal scarring, and /or excessively  
thick sebaceous skin. 
12. The inability to substantially lessen facial rhytides (fixed lines) even by [CONTACT_590278], as determined by [CONTACT_737] . 
13. Permanent make -up that would interfere with the assessment of facial wrinkles.  
14. Subjects who, in the Investigator ’s opi[INVESTIGATOR_1649], are unable or unwilling to maintain their 
standardized skin care regimen throughout the study period. 
15. Any eyebrow or eyelid ptosis at baseline as determined by [CONTACT_737].  
16. Infection or skin disorder at the injection sites.  
17. History of facial nerve palsy.  
18. Recent history (within 6 months of screening) of alcohol or drug abuse based on the 
Investigator ’s judgement . 
19. Anticipated need for surgery or overnight hospi[INVESTIGATOR_16366].  
20. Current enrollment in an investigational drug or device study or participation in such a study within 30 days  or 5 half -lives of the drug, whichever is longer , of ent ry into 
this study.  
 
Study Drug:  
 
 
 
Placebo : 
Sterile solution for injection with  
 
Dosage : 
The total dose will be the specified amount  of EB -001, or placebo, divided into 5  injections; 1 
injection into procerus at midline and a single injection into each of the medial and lateral corrugators bilaterally ( Figure S -1). Each subject will always receive 5  injections and the 
volume injected per site will be 0.1 mL. The spacing of injections into the lateral corrugators 
should be at or about 1 centimeter above the supraorbital ridge, which is known to minimize 
potential ptosis.  
 
Figure S–1 Injection Sites  
 
  
 
 

IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 18 of 93 Starting Dose  and Dose Escalation:  
Dose escalation scheme is shown in Table S -1 below . Additional doses (cohorts) may be 
explored as defined below in Flexibility in Dose Adjustment .   
 
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
 
  
 
   

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 19 of 93 Flexibility in Dose Adjustment: 
If an intolerable dose is identified, a lower dose may be evaluated.  This lower dose may be a 
repeat of the prior lower dose cohort or an intermediary dose between the intolerable dose 
and prior lower dose cohort.  
 
Any dose cohort below the intolerable dose cohort may be repeated, if requested by [CONTACT_587335], to better evaluate any finding at that dose level.  
 
All dose esc alation/adjustments or additional cohorts will be determined by [CONTACT_737190] a 
total of 9 dose cohorts for up to a total of 54 subjects.  
 
Screening : 
Written ICF, demographics, inclusion/exclusion criteria, medical history, physical and focused 
neurological examination s, height/weight, prior  and concomitant medications, triplicate 
ECG, clinical laboratory tests (serum chemistry, lipi[INVESTIGATOR_805], hematology, urinalysis), immunogenicity sample  collection , screens for human immunodeficiency virus (HIV) and 
hepatitis B and C, screens for alcohol and drugs of abuse, and serum  pregnancy test.  
 
Safety Assessments:  
Adverse events, physical and focused neurologic examinations, prior and concomitant 
medications, triplicate ECG, vital signs, clinical laboratory tests, medical history , and 
serum/ urine pregnancy test . 
 
Efficacy Assessments  
Investigator ’s and subject’s assessment of the FWS with Photonumeric Guide at maximum 
frown  and at rest . 
 
Other Assessments  
Standardized Facial Photography . 
 
General Statistical Considerations:  
The planned sample size will be approximately 42 subjects (35 for EB -001 and 7 for placebo)  
if all 7 cohorts are evaluated, or up to 54 subjects if additional 2 cohorts are evaluated .  All 

IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page [ADDRESS_1007048] 1 event detecting adverse events with given 
true event rate are shown in Table S-2: 
 
Table S –[ADDRESS_1007049] 
1 Event with 35 Subjects  
0.01  4.9% 29.7 % 
0.1 41.0 % 97.5 % 
0.2 67.2 % >99%  
0.5 96.9 % >99%  
 
Demographic and baseline charact eristics will be summarized.   Safety will be assessed by 
[CONTACT_202870], TEAEs, and serious adverse events.  Other 
safety parameters (clinical laboratory parameters, vital signs, and ECG measures), including 
mean absolute change from baseline, will be summarized by [CONTACT_1570].   Efficacy will 
be assessed by [CONTACT_737191] I nvestigator’s and subject’s 
assessment of GL severity at maximum frown and at rest using the FWS.  
 

IND 130880  18 November  2016 
 
 Confidential / Trade Secret  Page 21 of 93 

IND 130880  18 November 2016 
 
 
 Confidential / Trade Secret  Page 22 of 93 
 
 

IND 130880  18 November 2016 
 
 
 Confidential / Trade Secret  Page 23 of 93 
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 24 of 93 1 KEY ROLES  

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 25 of 93 2 INTRODUCTION  
2.1 Background Information  
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
  
  
 
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 26 of 93  
BoNT  serotype E (BoNT/E , EB-001) has been previously st udied in human subjects  with 
  
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
2.1.4 Nonclinical Evaluation of EB- 001 
EB-001 has been evaluated in a series of pharmacology and non -clinical toxicology studies  
 
 
 
  
  
 
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 27 of 93  
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page [ADDRESS_1007050] is 22 Units per ng and the recommended dosage for the 
 
 
 
  
 
  
  
  
 
  
 
 
 
   
 
  
2.2 Rationale  
2.2.1 Study Rationale  
This will be the FIH study of EB -001 to measure safety and efficacy in GL.  Single doses of EB -
001 administered through IM injection into procerus at midline and the medial and lateral 
corrugators will be assessed in healthy  subjects with glabellar frown lines .  
 
A total of 7 ascending dose cohorts are planned , or up to 9 cohorts if 2 additional cohorts 
are evaluated .  Each dose cohort will enroll a total of 6 subjects randomized to receive either 
EB-001 or placebo in a ratio  of 5 (active): 1 (placebo).  
 
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 29 of 93  
 
 
  
 
  
 
   
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 30 of 93   
  
  
  
  
  
  
  
  
 
 
 
Table 1  Likely symptoms from spread of botu linum toxin  
Body and Limbs Category  
• Decreased muscle tone  
• Loss of muscle function  
• Loss of muscle tone  
• Weakened reflexes  
• Lack of reflexes  
• Muscular weakness  • Muscle weakness of all four limbs  
• Partial loss of voluntary movement  
• Partial paralysis of one limb  
• Partial paralysis of one side of the 
body  
• Partial paralysis of the lower limbs  
• Pelvis muscle weakness  
Brain Category  
• Inability to send signals from your 
brain to your body  
• Interruption between brain and 
nerves in muscle   
Eyes Category  
• Abnormal pupil ref lex 
• Blurred vision  
• Double vision  
• Droopi[INVESTIGATOR_737174]  
• Eyelid function irregularity  
• Inability to focus or maintain a clear 
image  • Partial loss of eye movement  
• Partial loss of eye muscle movement 
(eyelid)  
• Partial loss of eye muscle movement (vertical glaze)  
Face Category  
• Loss of facial movement  
• Loss of feeling in face  • Loss of movement in face  
• Partial loss of feeling in face  
Heart and Lungs Category  
• Difficulty breathing  
• Inflammation of the lungs  
• Shortness of breath  • Slowed breathing  
• Slow heart rate  

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 31 of 93 Mouth Category  
• Difficulty speaking  
• Difficulty swallowing  
• Difficulty with motor skills (slurred 
speech, difficulty chewing and swallowing)  
• Dry mouth  
• Inability to move vocal cords  • Partial loss of facial motor functions 
(biting and chewing)  
• Partial loss of to ngue movement  
• Speech impediment  
• Stuttering  
• Weakness of vocal cords  
 
Stomach and Intestine Category  
• Bowe l blockage  
• Constipation  • Unable to urinate completely  
 
 Another risk is the possibility of an allergic reactions to drugs and to product ingredients. I f a 
subject has  a very bad allergic reaction, death  could occur . Likely signs or symptom s of 
allergic reaction s (anaphylaxis) that could be life -threatening are:  
• Rash. 
• Difficulty in breathing  or inability to breathe without assistance . 
• Wheezing . 
• Sudden drop in blood pressure (dizz iness ). 
• Swelling around the mouth, throat, or eyes . 
• Fast pulse . 
• Sweating . 
• Feeling of dread . 
 
The events of serious allergic reactions have been rare in the case of botulinum neurotoxin 
serotype A (for example, Botox® Cosmetic Label ). 
 Localized pain, infection, inflammation, tenderness, swelling, erythema, and/or bleeding/bruising may be associated with the injection.  
 
2.3.[ADDRESS_1007051].  
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 32 of 93 3 OBJECTIVES  AND PURPOSE  
This will be the FIH study of EB -001 to evaluate  safety and efficacy in GL.  
 
The s afety  objective is whether a  single treat ment cycle of EB -001 IM injections into the 
glabellar muscles ( procerus and bilateral corrugator mus cles) has an acceptable safety , and 
tolerability profile at the tested dose range .  
 The efficacy objection is whether a  single treatment cycle of EB -001 IM  injections, at one or 
more of the tested doses, is more effective than placebo in the treatment of GL assessed using the FWS.  
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 33 of 93 4 STUDY DESIGN AND ENDPOINTS 
4.1 Description of the Study Design  
This will be the F IH, multicenter, ascending dose cohort, randomized , double -blind, placebo -
controlled, single treatment cycle study of EB -001 IM injections in subjects with moderate to 
severe GL at maximum frown using Facial Wrinkle Scale  (FWS) .  Expected duration is 
approximately [ADDRESS_1007052] from the day of study treatment to the follow -up 
visit, and a pproximately 10 weeks  from signing informed consent form ( ICF) to the follow -up 
exit.  
 
 
 
. 
 
Placebo:  
Sterile solution for injection  
 
 
Dosage:  
Subjects in each cohort will be randomized to receive either EB-001 or placebo, and each 
cohort will receive a different dose level of EB- 001, which will generally be at a higher dose 
than the previous cohort, although dose modifications may be made depending on the 
safety and tolerability.   
 The total dose will be the specified amount  of EB -001, or placebo, divided into 5  injections; 1 
injection into procerus at midline and a single injection into each of the medial an d lateral 
corrugators bilaterally ( Figure 1).  Each subject will always receive 5  injections and the 
volume injected per site will be 0.1 mL.  The spacing of injections into the lateral corrugators 
should be at or about 1 centimeter above the supraorbital ridge, which is known to minimize 
potential ptosis.  
 There is no diet or w ater restriction throughout the study.  
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 34 of 93 Figure 1 Injection Sites  
 
  
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 35 of 93 4.1.1 Stop pi[INVESTIGATOR_737175] 2 or more subjects experiencing intolerable treatment emergent adverse 
 
 
 
 
 
  
 
  
 
  
 
  
 
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 36 of 93  
Table 3  Toxicity Criteria  
TEAE  Definition1 
Serious adverse event  See Section 8.1.2  
Related to  spread of toxin2 CTCAE ≥Grade  2 
Related to Laboratory and ECG parameters3 CTCAE ≥Grade  2 
All o ther s (other than th e SOT or laboratory and ECG parameters)  CTCAE >Grade  2 
Unspecified  If considered appropriate by [CONTACT_737192]  
 1 Unless considered to be unrelated to study medication  
 2 FDA Draft Guidance, Upper Facial Lines: Developi[INVESTIGATOR_77249] ( FDA 2014) . 
 [ADDRESS_1007053]  
Flexibility in Dose Adjustment:  
If an intolerable dose is identified (based on one of the above 3 criteria) , a lower dose may 
be evaluated.  This lower dose  may be a repeat of the prior lower dose cohort or an 
intermediary dose between the intolerable dose and prior lower dose cohort.  
 
Any dose cohort below the intolerable dose cohort may be repeated,  if requested by [CONTACT_587335], to better evaluate any finding at  that dose level.  
 
All dose escalation/adjustments or additional cohorts will be determined by [CONTACT_737190] a 
total of 9 dose cohorts for up to a total of 54 subjects.  
 
4.1.2 Follow -up of Subjects Meeting Stoppi[INVESTIGATOR_737176] 3 will be monitored carefully, which may include the 
following (to be agreed upon by [CONTACT_246792]):  
• Additional clinical laboratory tests and/or other investigations . 
• Additional outpatient visits.  
• Extended duration of follow -up. 
• Obtaining a specialist’s opi[INVESTIGATOR_1649].  
 
4.2 Study Endpoints  
4.2.1 Safety Endpoints  
• Incidence and severity of TEAEs and  serious adverse events (SAEs).  
• Focused neurologic examination  for potential SOT (See Appendix 1  for examination 
sheet) . 
• Incidence of abnormal findings in laboratory tests, electrocardiogram (ECG), physical 
exam ination , and vital signs (pulse rate, respi[INVESTIGATOR_697], and blood pressure).  
• Serum/urine pregnancy test fo r women of childbearing potential.  
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 37 of 93 4.2.2 Primary Efficacy Endpoint  
• The primary endpoint is the Investigator ’s assessment of GL severity at maximum 
frown using the FWS.  
 
The FWS is a four -point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = 
moderate, or 3 = severe (see Appendix 2  for sample FWS assessment sheet) . 
 
4.2.3 Secondary  Efficacy Endpoints  
• Investigator ’s assessment of GL severity at rest using the FWS.  
• Subject’s assessment of GL severity at maximum frown us ing the FWS.  
• Subject’s assessment of GL severity at rest using the FWS.  
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 38 of 93 5 STUDY ENROLLMENT  AND WITHDRAWAL  
Prior to shipment of study drug and before subjects  may be enrolled in the study, the 
Sponsor  or designee requires a copy of the following critical do cuments:  
• Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approval of 
the protocol and the subject  Information Sheet / Informed Consent Form (ICF);  
• Signed and dated protocol signature [CONTACT_3264];  
• Completed Food and Drug Administration (FDA) Form 1572 (central laboratories and 
any local laboratories for the study must be listed on the form);  
• Up-to-date curricula vitae and medical licenses (if applicable) of the Principal 
Investigator  (PI) and all Sub -Investigator s listed on the FDA For m 1572;  
• Signed financial disclosure forms for the Principal Investigator  (PI) and all Sub -
Investigator s listed on the FDA Form 1572;  
• Name, address, and membership of the IRB/IEC;  
• Laboratory normal ranges and documentation of laboratory certification (or equivalent);  
• Signed clinical study agreement;  
 All subjects must personally sign and date an IRB -approved ICF before any study procedures, 
including screening procedures, are performed.  Subjects will be considered enrolled into the study only when they have received study drug.   
 
5.[ADDRESS_1007054] meet ALL of the 
following criteria:  
1. Signed and dated IRB -approved informed consent  form (ICF).  
2. Men or women between the  ages of 18 and 60, inclusive.  
3. Subjects in good health as determined by [CONTACT_9870], physical and focused 
neurological  examination s, clinical laboratory studies, electrocardiograms (ECGs), 
vital signs, and Investigator ’s judgement . 
4. Presence of bilatera lly symmetrical GL of moderate to severe rating at maximum 
frown, as measured using FWS by [CONTACT_737189].  
5. Subjects with  sufficient visual acuity without the use of eyeglasses (contact [CONTACT_442248]) to accurately assess their facial wrinkles  as determined by [CONTACT_3786] ’s judgement . 
6. Women of child bearing potential must not be pregnant, lactating, or planning to 
become pregnant during the study.  
7. Women of non -childbearing potential must be either postm enopausal  (at least 12 
consecutive months  of amenorrhea ) or surgically sterile (e.g., tubal ligation, 
hysterect omy, etc.).  
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page [ADDRESS_1007055] 2  months prior to the day of 
dosing.   
9. Male subjects with partner(s) of childbearing potential agree ing to use dual methods 
of contraception from the day of dosing until 3  months a fterwards, and to no sperm 
donation from day of dosing until 3  months afterwards.  
10. Willing and able to complete protocol requirements and instructions, which includes 
completion of all required visits.  
 
5.2 Participant Exclusion Criteria  
An individual who meets  ANY  of the following criteria will be excluded from participation in 
this study:  
1. Any condition that precludes a subject’s ability to comply with study requirements, 
including completion of the study visits or inability to read, understand, and/or self -
assess GL severity using FWS.  
2. Any uncontrolled systemic disease or other medical condition.  
3. Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including diagnosed myasthenia gravis, Eaton-Lambert  syndrome, amyotrophic lateral sclerosis, or any other condition that might 
interfere with neuromuscular function.  
4. Current or previous botulinum toxin treatment of any serotype.  
5. Anticipated need for treatment with botulinum toxin of any serotype for any re ason 
during the study (other than study treatment).  
6. Known immunization or hypersensitivity to any botulinum toxin serotype.  
7. Known allergy or sensitivity to any of the components of the study treatments, or any materials used in the study procedures.  
8. Any of  the following procedures or treatments occurring with in the specified period 
prior to  screening : 
o 3 months: Non -ablative resurfacing laser or light treatment, microdermabrasion, 
or superficial peels.  
o 6 months: Any facial cosmetic procedure with medium dept h to deep facial 
chemical peels (e.g., trichloroacetic acid [TCA] and phenol), or mid facial or 
periorbital laser skin resurfacing.  
o 6 months: On topi[INVESTIGATOR_737172]/or topi[INVESTIGATOR_737177], who have not been on a co nsistent do se regimen and are unable to 
maintain  the same regimen for the study . 
o 12 months: Mid- facial or periorbital treatment with non -permanent soft tissue 
fillers.  
o 12 months: O n oral retinoid therapy.  
9. Prior periorbital surgery, facial lift (full face or mid face) , brow lift, or related 
procedures (e.g., eyelid [blepharoplasty] and/or eyebrow surgery).  
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 40 of 93 10. Prior mid face or periorbital treatment with permanent soft tissue fillers, synthetic 
implantation (e.g., Gore -Tex®), and/or autologous fat transplantation.  
11. Marked f acial asymmetry, dermatochalasis, deep dermal scarring, and /or excessively  
thick sebaceous skin.  
12. The inability to substantially lessen facial rhytides (fixed lines) even by [CONTACT_590278], as determined by [CONTACT_737] . 
13. Permanent make -up that would interfere with the assessment of facial wrinkles.  
14. Subjects who, in the Investigator ’s opi[INVESTIGATOR_1649], are unable or unwilling to maintain their 
standardized skin care regimen throughout the study period.  
15. Any eyebrow or eyelid ptosis at baseline as d etermined by [CONTACT_737] . 
16. Infection or skin disorder at the injection sites.  
17. History of facial nerve palsy.  
18. Recent history (within 6 months of screening) of alcohol or drug abuse based on the 
Investigator ’s judgement . 
19. Anticipated need for surgery or o vernight hospi[INVESTIGATOR_16366].  
20. Current enrollment in an investigational drug or device study or participation in such a study within [ADDRESS_1007056] may be terminated  from the study for any of the following rea sons:  
• Withdrawal of informed consent.  
• Entry into the study in violation of the protocol.  
• Any AE, laboratory abnormality, or other medical condition or situation occurs such that the study doctor or study staff believes  continued participation in the study 
would not be in the best interest of the participant.   
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 41 of 93 • The participant meets an exclusion criterion (either newly developed or not 
previously recognized) that precludes further study participation.   
• Noncompliance  with the protocol.  
• At the discretion of the  Investigator  or Sponsor  for any reason.  
 
5.4.[ADDRESS_1007057] 
early termination (ET) evaluations as thoroughly as possible up to the da te of withdrawal at 
the time of discontinuation.    
 Subjects  who discontinue from the study  may be replaced  unless it is due to one of the 
toxicity criteria in Table 3, in which situation subjects will not be repla ced. 
 
5.5 Premature Termination or Suspension of Study  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided  by [CONTACT_737193]. If the study is 
prematurely terminated or suspended, the PI [INVESTIGATOR_33894](s) for the termination or suspension.  
 Circumstances that may warrant termination or susp ension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants . 
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007] . 
• Insufficient compliance to protocol requirements . 
• Data that are not sufficiently complete and/or evaluable . 
• Determination of futility . 
 Study may resume once concerns about safety, protocol compliance, and/or data quality are addressed and satisfy the Sponsor , IRB and/or FDA.  
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 42 of 93 6 STUDY AGENT  
 
 
  
  
 
 
   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
  
 
 
 
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 43 of 93 6.1.5 Dosing and Administration  
See Section 4.1. 
 
6.1.6 Route of Administration  
Intramuscular  
 
6.1.7 Starting Dose  and Dose Escalation Schedule  
See Section 4.1. 
 
6.1.8 Dose Adjustments/Modification/Delays  
If an intolerable dose is identified, a lower dose may be evaluated.  This lower dose may be a 
repeat of the prior lower dose cohort or an intermediary dose between the intolerable dose 
and prior lower dose cohort.  
 
Any dose cohort below the intolerable dose cohort may be repeated,  if requested by [CONTACT_587335], to better evaluate any finding at that dose level.  
 
All dose escalation/adjustments or additional cohorts will be determined by [CONTACT_737190] a total of [ADDRESS_1007058] (screening) to the last visit of the last subject . 
 
6.1.[ADDRESS_1007059] the dispenser  or design ee to ship any remaining  study vials  to the 
distribution center to be destroyed.  
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page [ADDRESS_1007060]  
Instructions for resupply shipments or replacement of study drug are referenced in the  
study manual(s) . 
 
6.[ADDRESS_1007061] be 
maintained using the forms provi ded study manual(s) . 
 All study drug documentation must be maintained by [CONTACT_737194].  All disposition records must be made available for 
inspection by [CONTACT_737195].  
 A Study Drug Kit Log  will b e provided for the accounting of study drug.  Study Drug Kit L og 
forms will be provided for the accounting of study drug for each study subject and for 
maintaining the overall balance of vials .  A reason(s) must be given for any amounts  that are 
not accoun ted for.  
 Each site must keep all  remaining study drug  in the original vials  until the y are  returned  to 
the distribution center.   
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 45 of 93 7 STUDY PROCEDURES AND S CHEDULE  
7.1 Study Procedures/Evaluations  
The principal Investigator  [INVESTIGATOR_737178] t and content of the ICF 
before it is submitted to the IRB for approval.  Written informed consent must be obtained 
from each subject prior to any study -related activities being conducted.  The Investigator  
must retain all original signed and personally da ted ICFs (together with any subsequent IRB -
approved amended versions) in the subject’s file.  A copy of the original signed and dated ICF 
(and any amendments) must be given to the subject.   
 
Subjects will be informed of findings (including AEs) from earli er cohorts if it is considered 
these could potentially affect the subject’s willingness to participate or continue in the 
study.  Depending on the nature, severity, and seriousness of these AEs, the ICF may be amended.  
 
7.1.1 Study Specific Procedures  
• Informed C onsent  
• Demographics  
• Assessment of inclusion/exclusion criteria  
• Medical history  
• Assessment of adverse event  
• Height and weight 
• Complete physical and focused neurological examination s 
• Mini Physical and focused neurological examination s 
• Prior and concomitant m edications  
• 12-lead ECG  
• Body temperature, respi[INVESTIGATOR_1487], blood pressure, and pulse rate  
• Serum chemistry, Lipi[INVESTIGATOR_805], Hematology  
• Urinalysis  
• Immunogen icity sample collection  
• Screens for HIV and hepatitis B and C  
• Screens for alcohol / drugs of abuse  
• Serum/u rine pregnancy test 
• Study drug administration 
• Standardized Facial Photography  
• Facial Wrinkle Scale – Subject Assessment  
• Facial Wrinkle Scale – Investigator  Assessment  
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 46 of 93 [IP_ADDRESS]  Informed Consent  
At the Screening  Visit, prior to any procedures are performed, the site s taff will obtain the 
signed ICF from each participant.  
 
[IP_ADDRESS]  Demographics  
At the Screening  Visit, the site staff will be responsible for collecting the age, sex, ethnicity, 
and race.  
 
[IP_ADDRESS]  Assessment  of Inclusion/ Exclusion Criteria  
At the Screening and the Baseline (prior to dosing) Visit s, the site staff will be responsible 
for reviewing the inclusion and exclusion criteria to determine the subject’s  eligibility for the 
study.   
 
[IP_ADDRESS]  Medical  History  
At the Screening  Visit, medical history of the subject will be conducte d.  Any untoward 
medical occurrence that occurs after signing ICF  is considered AE.  
 
[IP_ADDRESS]  Assessment of Adverse Event  
Adverse events will be recorded beginning after signing the ICF until completion of the study  
until the final follow -up visit (Day 42) , and wil l be evaluated by [CONTACT_737196] 
(using CTCAE version 4.03  criteria (CTCAE 2010) ), seriousness, and attributability to study 
medication.  Further details on AEs, including definitions, elicitation, and repor ting are 
provided in Section 8. 
 
[IP_ADDRESS]  Height  and Weight  
At the Screening  Visit , subject height will be recorded.  Height  (cm) measured from the 
Screen Visit will be carried forward to Day 0.   At the Screening  and Baseline (prior to dosing) 
Visit s, subject weight  (kg, in indoor clothing, but without shoes)  will be measured.     
 
[IP_ADDRESS]  Complete Physical and Focused  Neurological Examination s 
At the Screening and the Baseline (prior to dosing) Visits , complete p hysical examinations 
(including b ut not limited to: dermatologic , head, eye, ear, nose, throat ( HEENT ), respi[INVESTIGATOR_696], 
cardiovascular, abdomen, lymph nodes, mus culoskeletal) will be performed.  Focused  
neurological examination will  assess potential SOT  per instructions in the Appendix 1 . 
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 47 of 93 [IP_ADDRESS]  Mini Physical and Focused  Neurological Examination s 
At Days 1, 2, 7, 14, 30 (EOS/ET) , and 42 Visit s, mini physical examin ation  that is symptom -
oriented will be performed.   Focused  neurological examination will assess potential SOT per 
instructions in  the Appendix 1 . 
 
[IP_ADDRESS]  Prior and C oncomitant  Medications  
At the Screening Visit, the Baseline Visit, and at all subsequent scheduled and unscheduled 
clinic visits , prior and concomitant medications will be asse ssed.  
 
Medications taken within 30 days prior to the screening visit and up to the study drug 
administration will be considered to be prior medications.  Concomitant medication is defined as any medication that is taken after the s tudy  drug administration (Day 0).  Any use 
of prior and concomitant medications will be recorded on the Concomitant Medications 
electronic Case Report Form (eCRF).  During the study, initiation of or change in concomitant 
medications to treat an AE must  also be recorded on an AE e CRF for that AE.  
 
[IP_ADDRESS]  12-Lead ECG 
At the Screening Visit, Day 2 Visit , and Day 30 (EOS/ET) Visit, a standard [ADDRESS_1007062].  All ECG measures will be performed in triplicate, with each consecu tive measure approximately 1 minute apart.  In 
addition, where applicable, ECGs will be performed prior to blood draws . 
 The definitive ECG assessments will be conducted by a central ECG -reading facility.  The 
assessment of the ECG by [CONTACT_737197] -readi ng facility will include heart rate (HR), ECG 
intervals/durations ( RR interval, PR interval, QRS duration, QT interval, and QT
c interval 
using Fridericia’s and Bazett’s corrections [QT cF and QT cB intervals, respectively; see  List of 
Abbreviations and G lossary of Terms ), and assessments of the waveform.  The tracings may  
be reviewed and reported both locally and by a blinded central reader.  In the event that the clinical study site and the central reader disagree on the interpretation of the results, the 
central reader’s interpretation will be considered final.  The centrally reported ECG results 
will be used in the data analyses.  
 
[IP_ADDRESS]  Body Temperature, Respi[INVESTIGATOR_1516] R ate, Blood Pressure, and P ulse Rate 
At the Screening Visit, Baseline Visit (Day 0), and at all subsequent scheduled clinic visits  till 
Day 30 (EOS/ET) visit, vital signs including b ody temperature, respi[INVESTIGATOR_1487], blood 
pressure, and pulse rate will be recorded .  In addition, where applicable, vital sign d ata will 
be collected  prior to blood draws . 
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 48 of 93 Body temperature taken either orally or aurally  will be the same throughout the study .  
Respi[INVESTIGATOR_737179] a quiet resting state prior to blood pressure (BP) and pulse 
rate measurements.  Supi[INVESTIGATOR_9204] (BP; systolic and diastolic) and pulse rate will be 
evaluated after at least [ADDRESS_1007063].   
 
[IP_ADDRESS]  Serum Chemistry , Lipi[INVESTIGATOR_805], Hematology  
At the Screening Visit, Day 7 Visit, and Day 30 (EOS/ET) Visit, samples for routine serum 
chemistry, lipi[INVESTIGATOR_805], and hematology will be collected  (see Appendix 3  for specific tests) .  
Fasting for serum chemistry and lipi[INVESTIGATOR_737180].  
 The samples will be analyzed by a central  laboratory (with the appropriate accreditations or 
certifications).  If clinically indicated, tests may be taken at additional times.  Any clinical laboratory findings considered to be clinically significant changes from screening will be recorded as an AE on the eCRF (unless the laboratory finding is a feature of a specific diagnosis, when only the diagnosis will be recorded).   Any clinically significant abnormal 
values that persist will  be followed until they have been resolved or the Investigator , in 
consultation with the Medical Monitor or designee , assesses them to be chronic or stable.  
 
[IP_ADDRESS]  Urinalysis  
At the Screening Visit, Day 7 Visit, and Day 30 (EOS/ET) Visit, urine samples for urinalysis will 
be collected  (see Appendix 3  for specific tests).   
 The samples wi ll be analyzed by a central laboratory (with the appropriate accreditations or 
certifications).  If clinically indicated, tests may be taken at additional times.  Any clinical laboratory findings considered to be clinically significant changes from screeni ng will be 
recorded as an AE on the eCRF (unless the laboratory finding is a feature of a specific diagnosis, when only the diagnosis will be recorded).   Any clinically significant abnormal 
values that persist will be followed until they have been resolved or the Investigator , in 
consultation with the Medical Monitor or designee, assesses them to be chronic or stable.  
 
[IP_ADDRESS]  Immunogen icity Sample Collection  
 
 
 
[IP_ADDRESS]  Screens for HIV and Hepatitis B and C  
At the Screening Visit only, blood samples for testing HIV antibody, hepatitis B surface 
antigen, and hepatitis C antibody will be collected.  
 

IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 49 of 93 The samples will be analyzed by a central  laboratory (with the appropriate accreditations or 
certifications).  Any positive findings at the Screening will exclude subject from participating 
in the study . 
 
[IP_ADDRESS]  Screens for A lcohol / D rugs of A buse 
At the Screening Visit, Baseline (prior to dosing) Visit, Day 7 Visit, and Day 30 (EOS/ET) Visit, 
urine samples for screening drugs of abuse and saliva samples for screening alcohol will be 
collected  and performed  (see Appendix 3  for specific tests) .   
 
The samples will be analyzed  at the study site .  Any positive findings at the Screening or 
Baseline Visit will exclude subject from participating in the study . 
 
[IP_ADDRESS]  Pregnancy  Test 
At the Screen ing Visit, blood  samples for pregnancy test for women of child bearing 
potential will be collected.  The samples will be analyzed by a central  laboratory (with the 
appropriate accreditations or certifications).   
 At the Baseline (prior to dosing) Visit an d Day 30 (EOS/ET) Visit, urine samples for pregnancy 
test for women of child bearing potential will be collected.  The samples will be analyzed at the study site .  Any positive findings at the Screening or Baseline Visit will exclude subject 
from participa ting in the study .  See Section 8.5.2  in the event of a ny positive findings during 
the study . 
 
[IP_ADDRESS]  Study  Drug Administration  
At the Baseline  Visit , upon conducting all specified pre -dose assessment and confirming 
subjects remain eligible for the study, study drug will be administered.  Six subjects in a 
cohort will be treated with either EB -001 or placebo in a ratio of 5:1 in a double -blind 
manner.  
 
[IP_ADDRESS]  Standardized Facial  Photography  
At the Baseline (prior to dosing) Visit, and at all subsequent scheduled clinic visits  till Day 30 
(EOS/ET) visit, standardized facial photographs will be taken per instructions in the study 
manual(s) . 
 The facial photograph  assessments will be conducted by a central facility.  Results from the 
assessments will be used for reference purpose only and not be used to influence efficacy endpoint assessment at the site.  
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 50 of 93 [IP_ADDRESS]  Facial Wrinkle Scale –  Subject  Assessment  
At the Screening Visit, Baseline (prior to dosing) Visit, and at all subsequent scheduled clinic 
visits  till Day 30 (EOS/ET) visit, FWS at maximum frown  and at rest will be assessed by [CONTACT_1560].  Subjects will be provided the Photonumeric Guide prior to self -assessment to assist 
and standardize grading of GL severity.  The FWS is a four -point scale that indicates severity 
of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe  (see Appendix 2  for sample 
FWS assessment sheet) . 
 
[IP_ADDRESS]  Facial Wrinkle Scale –  Investigator  Assessment  
At the Screening Visit, Bas eline (prior to dosing) Visit, and at all subsequent scheduled clinic 
visits  till Day 30 (EOS/ET) visit, FWS at maximum frown  and at rest will be assessed by [CONTACT_3786] .  Investigator will be provided the Photonumeric Guide prior to assessment to 
assist and standardize grading of GL severity.   The FWS is a four -point scale that indicates 
severity of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe (see Appendix 2  for 
sample FWS assessment sheet) . 
 
7.2 Laboratory  Procedures/Evaluations  
7.2.1 Clinical Laboratory Evaluations  
See Sections [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS] , [IP_ADDRESS], and  [IP_ADDRESS].  
 
7.2.2 Specimen Preparation, Handling, and Storage  
See Laboratory Manual for instructions of  specimen preparation, handling, and storage.  
 
7.2.3 Specimen Shipment  
See Laboratory Manual for instruction of specimen shipment.  
 
7.2.4 Volume of Blood Collected  
The estimated total blood volume collected throughout the study for clinical laboratory  and 
immunogen icity tests is summarize d in Table 4 and is expected to be approximately  59.5 mL. 
 
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page [ADDRESS_1007064]  Blood Sample Volume  Number of Tests  Total Volume  
Hematology1 4 mL  3 12 mL 
Serum chemistry1, Lipi[INVESTIGATOR_805], Serum 
pregnancy test2 8.5 mL 3 25.5  mL 
HIV 1/O/2  5 mL  1 5 mL 
HBsAG and HCV Ab  5 mL  1 5 mL 
Serum  samples for immunogenicity  4 mL 3 12 mL 
TOTAL    59.5 mL 
1  Additional blood may be collected for safety laboratory tests, i f clinically indicated  
2  Female of child bearing potential only  
 
7.3 Study Schedule  
7.3.1 Screening Visit (Days - 30 to -1) 
Screening (Visit 1, Days -30 to -1, inclusive ) will include the procedures and evaluations set 
forth in Section 7.3.7. 
 
7.3.2 Baseline Visit  (Day 0) 
Baseline measurements and  confirmation of subject eligibility  will take place on Day 0. 
Procedures and evaluations prior to and after dose administration are set forth in Section 
7.3.7 . 
 
7.3.3 Follow -Up Visits  (Days 1, 2, 7, AND 14)  
Follow -up visits will take place on Days 1  (±2 hours) , 2 (±4 hours) , 7 (±12 hours) , and 14 (±1 
day) .  All procedures in each visit  will be performed within the specified window.   Procedures 
and evaluations for each follow -up visit are set forth in Section 7.3.7 . 
 
7.3.4 End of Study  (Day 30) / Early Termination Visit  
Subject is considered to have completed the study after procedures and evaluations of Day 
30 (±2 days) are performed.  All procedures will b e performed within the specified window.   
End of study (EOS) visit will include p rocedures and evaluations set forth in Section 7.3.7 . 
 In the event of early termination  (ET), every attempt should be made to have subject return 
to the site to complete procedures and evaluations set forth in Section 7.3.7.  
 
7.3.5 Final Follow -Up Visit  
The final follow -up visit on Day 42  (±2 days ) will include the procedures and evaluations  set 
forth in Section 7.3.7 .  All procedures will be performed within the specified window.    
IND 130880  18 November  2016 
 Confidential / Trade Secret  Page 52 of 93  
7.3.6 Unscheduled Visit  
Unscheduled Visit , at the discretion of the Investigator , may occur and appropriate 
procedures and evaluations will be conducted and documented in the eCRF .   
IND 130880  18 November 2016 
 
 
 Confidential / Trade Secret  Page 53 of 93 
 
 7.3.7 Schedule of Events Table  

IND 130880  18 November 2016 
 
 
 Confidential / Trade Secret  Page 54 of 93 
 
   
  
  
  
  
  
  
  
 
 
  
  
  
 
  
  
 
  

IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 55 of 93 
 7.4 Concomitant  Medications and Treatments  
Throughout the study, the following concomitant medications and treatments  are allowed 
and will be recorded.  
• Regular moisturizer or sunblock creams or lotions . 
• Medications used for co ntrolled systemic disease or other medical condition s. 
• Vitamins and herbal medicines.  
• Acetaminophen for symptomatic relief of pain  on an as needed basis, as prescribed  
by [CONTACT_737] .   
 
The Investigator  must notify the Sponsor  if participants take other concomitant medi cations 
during the study.  The decision to allow the subject to be enrolled into the study or take medications during the study will be made jointly by [CONTACT_403000] , based on 
their opi[INVESTIGATOR_737181].  
 
7.[ADDRESS_1007065] following 
treatments/procedures performed until after the EOS Visit . 
• Any topi[INVESTIGATOR_737182] a consistent dose regimen and  maintain ed the same regimen for 
at least 6 months before  enrollment . 
• Any oral retinoid drugs  within 12 months of enrollment.  
• Any drug s used for skin conditions  within 3 months of enrollment.   
• Any non -ablative resurfacing laser or light treatment, microdermabrasion, superficial 
peels within 3 months of enrollment.  
• Any facial cosmetic procedure with medium depth to deep facial chemical peels (e.g., 
trichloroacetic acid [TCA] and phenol), or mid facial or periorbital laser skin resurfacing  within 3 months of enrollment.  
• Any m id-facial or periorbital treatment with non -permanent soft tissue fillers  within 
12 months of enrol lment.  
• Any history of  botulinum neurotoxin treatment of any serotype . 
 
7.[ADDRESS_1007066] Restriction  
The following restrictions apply:  
• Female of childbearing potential must agree to use dual methods of contraception 
from the day of dosing for [ADDRESS_1007067] 2  months prior to the day of dos ing.   
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 56 of 93 
 • Male subjects with partner(s) of childbearing potential must agree to use dual 
methods of contraception from the day of dosing for 3 months, and to n o sperm 
donation from day of dosing until 3  months afterwards.  
• Subjects must not donate blood or plasma from [ADDRESS_1007068] follow -up visit (Day 42) . 
• Subjects should not consume more than moderate amount of alcohol per day (i.e.,  1 
drink per day for women or 2 drinks per day for men).  
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 57 of 93 
 8 ASSESSMENT OF SAFETY  
8.1 Specification of Safety Parameters  
All of the following safety endpoints will be recorded on the e CRF. 
• Incidence and severity of TEAEs and SAEs.  
• Focused neurologic assessment  for potential SOT . 
• Incidence of abnormal findings in laboratory tests, ECG, physical examination, and 
vital signs (pulse rate, respi[INVESTIGATOR_697], and blood pressure) . 
• Urine pregnancy test for women of childbearing potential . 
 
8.1.1 Definition of Adverse Even ts (AE)  
Information about adverse events, whether reported by [CONTACT_423], discovered by [CONTACT_737198]/review of diary records or detected through physical 
examination, laboratory test or other means, will be collected and recorded on th e adverse 
event form and followed -up as appropriate.  Information about serious adverse events must  
be reported within 24 hours of obtaining knowledge of the event.  
 An adverse event  (AE), defined according to  International Committee on Harmonisation  
(ICH)  Harmonized Tripartite Guideline E2A  (FDA 1995) , is any untoward medical occurrence 
in a subject or clinical trial subject administered a trial product and which does not 
necessarily have a causal relationship with this trea tment.  An AE can therefore be any 
unfavorable and unintended sign (including a laboratory finding, for example), symptom, syndrome, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal pr oduct.  Examples include:  
• Any treatment -emergent signs and symptoms [events that are marked by a change 
from the subject ’s baseline/entry status (e.g., an increase in severity or frequency of 
pre-existing  abnormality or disorder)];  
• All reactions from s tudy drug, abuse of drug, withdrawal phenomena, sensitivity, or 
toxicity to study drug;  
• Apparently unrelated illnesses;  
• Injury or accidents;  
• Exacerbations of the underlying disease (indication),  
• Extensions or exacerbations or symptomatology, subjec tive events reported by [CONTACT_1560], new clinically significant abnormalities in clinical laboratory, physiological testing, or physical examination.  
 The following is not considered an AE:  
• Pre-planned procedure (documented as concomitant illness on the CR F at screening) 
unless the condition for which the procedure was planned has worsened from the first trial related activity after the subject has signed the informed consent form.  
• Pre-existing conditions found as a result of screening procedures.  
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 58 of 93 
  
8.1.2 Definition of Serious Adverse  Events (SAE)  
In addition to the severity rating, each AE is to be classified by [CONTACT_179821] “serious” 
or “not  serious.”  The seriousness of an event is defined according to the applicable 
regulations and generally refers to t he outcome of an event.  A  serious adverse event (SAE) is 
one that meets one or more of the following:  
• Is fatal.  
• Is immediately life -threatening . 
• Is permanently (or significantly) disabling . 
• Requires hospi[INVESTIGATOR_059].  
• Prolongs existing hospi[INVESTIGATOR_059] . 
• Is a congenital anomaly or birth defect (in an offspring) . 
• Is judged medically significant.  
 
Definition of Life -threatening  
Places the subject, in the view of the Investigator , at immediate  risk of death from the event 
as it occurred.  This does not include an  adverse event, which, had it occurred in a more 
severe form, might have caused death.  
 
Definition of Hospi[INVESTIGATOR_542686] a full admission to the hospi[INVESTIGATOR_431800].  This includes prolongation of an existing inpatient hospi[INVESTIGATOR_059].  
 
Examples of visits to a hospi[INVESTIGATOR_431801]:  
• Emergency room visits (that do not result in a full hospi[INVESTIGATOR_063]) . 
• Outpatient surgery . 
• Preplanned or elective procedures (See Section  [IP_ADDRESS] ). 
• Protocol procedures . 
 
These events would not  be reported as SAEs unless:  
• The event triggering the hospi[INVESTIGATOR_737183] -threatening, re sults in persistent or significant disability/incapacity or as per 
medical judgement  of Investigator . 
• Any other event fulfilling the definition of serious that develops as a result of the in -
hospi[INVESTIGATOR_737184].  
 
Defin ition of Disability  
Disability is defined as a substantial disruption in a person’s ability to conduct normal life functions.  
 
Definition of Medically Significant  
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 59 of 93 
 Important medical events (medically significant events) that may not result in death, be life -
threatening or require hospi[INVESTIGATOR_149693], based upon 
appropriate medical judgement , they may jeopardize the subject or may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.   Examples of 
such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], or 
development of drug dependency or drug abuse.  
 
An SAE may also include any other event that the Investigator , or Medical Monitor or 
designee  judges to be serious, or that suggests a significant hazard, contraindication, side 
effect, or precaution.  
 
[IP_ADDRESS]  Elective Procedures, and Surgeries  
For the purposes of this Protocol, the follo wing conventions will apply for SAE reporting of 
elective procedures, and surgeries:  
 
A pre -scheduled elective procedure or a routinely scheduled treatment is not to be 
considered an SAE, even if the subject is hospi[INVESTIGATOR_057], provided the site stipulates that:  
• The condition requiring the pre -scheduled elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress between the subject ’s 
consent to participate in the clinical trial and the time of the procedure or treatmen t. 
• The pre -scheduled elective procedure or routinely scheduled treatment is the sole 
reason for admission and intervention.  
 An untoward medical event occurring during the pre -scheduled elective procedure or 
routinely scheduled treatment must  be recorded a s an AE or a SAE.  Record a ny concurrent 
medications on the eCRF.  
 
8.1.3 Definition of Unanticipated Problems  (UP)  
The Office of Human Research Protection (OHRP) considers unanticipated problems involving risks to participants or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol -related documents, such as the IRB -
approved research protocol and informed consent document; and (b) the characteristics of the participant population being studied . 
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]) . 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 60 of 93 
 • Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously known  or recognized.  
 This study will use the OHRP definition of UP .
 
 
8.2 Classification of an Adverse Event  
8.2.1 Severity of Event  
AEs will be assessed according to the CTCAE version 4.03  (CTCAE 2010) .  AEs that do not 
have a correspo nding CTCAE term will be assessed according to their impact on the 
participant’s ability to perform daily activities as listed below.  
• Mild (grade 1): The AE does not interfere in a significant manner with the subject’s normal functioning level —it may be an  annoyance.  
• Moderate (grade 2): The AE produces some impairment of functioning, but is not 
hazardous to health— it is uncomfortable or an embarrassment.  
• Severe (grade 3): The AE produces significant impairment of functioning or 
incapacitation and is a defin ite hazard to the subject’s health.  
• Life threatening (grade 4): Life threatening or disabling.  
• Fatal (grade 5): Causes death of the participant.  
 These five categories are based on the Investigator ’s clinical judgement , which in turn 
depends on considerati on of various factors such as the subject ’s reports, the physician’s 
observations, and the physician’s prior experience.  Record t he severity of the AE in the 
appropriate section of the AE page of the eCRF.  The evaluation of severity is distinguished 
from  the evaluation of “seriousness” (see Section  8.1.2 ).  A severe event might not meet the 
criteria for seriousness and a serious event might be evaluated as mild.  For example, a 
subject  might have a severe headache that does no t require hospi[INVESTIGATOR_737185] ; or a subject might have a mild  myocardial infarction that requires 
hospi[INVESTIGATOR_636918] . 
 
8.2.[ADDRESS_1007069]  be assessed and cl assified by [CONTACT_179821] 
“related” or “ unrelated”.  An event is considered related  if there is “a  reasonable possibility” 
that the event may have been caused by [CONTACT_95107] (i.e., there are 
facts, evidence, or arguments to sugges t possible causation).  
 
Categories of attribution for “Related” events:  
• Definitely related: There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out.  
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 61 of 93 
 • Probably related: There is evidence to suggest a  causal relationship, and the 
influence of other factors is unlikely.  
• Possibly related: There is some evidence to suggest a causal relationship (e.g., the 
event occurred within a reasonable time after administration of the study drug). 
However, the influen ce of other factors may have contributed to the event (e.g., the 
subject’s clinical condition, other concomitant events).  
Categories of attribution for “Unrelated” events:  
• Unlikely related: There is little evidence to suggest there is a causal relationship . 
There is another reasonable explanation for the event.  
• Not related: An AE  will be considered “not related” to the use of the product if any 
of the following tests are met:  
o An unreasonable temporal relationship between administration of the product and th e onset on the AE (e.g., the event occurred either before, or too long after 
administration of the product for it to be considered product- related);  
o A causal relationship between the product and the AE is biologically implausible (e.g., death as a passenge r in an automobile accident);  
o A clearly more likely alternative explanation for the AE is present (e.g., typi[INVESTIGATOR_56664] a concomitant drug and/or typi[INVESTIGATOR_5194] -related event).  
 
Consider the following when assessing causality:  
• Temporal associations between the agent and the event.  
• Cessation or rechallenge.  
• Compatibility with known class effect . 
• Known effects of concomitant medications . 
• Pre-existing risk factors.  
• A plausible mechanism.  
• Concurrent illnesses.  
 
8.2.3 Expectedness  
Sponsor  will be respons ible for determining whether an AE is expected or unexpected.  An 
AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agen t. 
 
8.3 Time Period and Fre quency for Event Assessment and Follow -up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor.   All AEs includi ng local and systemic reactions not meeting the 
criteria for SAEs will be captured on the appropriate eC RF. Information to be collected 
includes event description,  dates and times of onset and resolution, clinician’s 
assessment of severity, assessment of r elatedness to study drug  (assessed only by [CONTACT_26563] a diagnosis), and action taken . All AEs occurring 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page [ADDRESS_1007070] be documented appropriately regardless of relationship. All AEs will 
be followed to adequate reso lution.  
 Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE.  However, if the study participant’s 
condition deteriorates at any time during the study, it will be reco rded as an AE.  UPs will 
be recorded in the data collection system throughout the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration 
of the event at each level of severity to be performed.  AEs characterized  as intermittent 
require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 
The Investigator  will record all reportable events with start dates occurring any time after 
informed consent is obtained until  the AE has  resolved, stabilized, or a new chroni c baseline 
has been established.  At each study visit, the Investigator  will inquire about the occurrence 
of AE/SAEs since the last visit. Events will be followed for outcome information until 
resolution or stabilization.  
 
8.[ADDRESS_1007071]’s  medical notes.  The following attributes must be 
assigned: event description, dates  and times  of onset and resolution, clinician’s assessment 
of severity, assessment of relatedness to study drug (either related or not related), and 
action taken.  The Investigator  may be asked to provide additional follow -up information.  
 In the event that a subject  is withdrawn from the study because of an AE, it must be 
recorded on the eCRF.  The subject must  be followed and treated by [CONTACT_737199], stabilized, or a new chronic baseline has been established.  
 The Investigator  must report all observed AEs and  all reported AEs.  At each visit the 
Investigator  will ask the subject  a nonspecific question (e.g., “Have you noticed anything 
different since your last visit?”) to assess whether any AEs have been experienced since the last report or visit.  AEs will be  identified and documented on the AE page of the eCRF in 
appropriate medical terminology.  The severity and the relationship to the study drug will be determined and reported on the eCRF (see Sections 8.1.1  and 8.2.2 ). 
 Note that any intermittent or as -needed (“PRN”) use of medication (and specifically any 
newly prescribed medication) during the course of a study may indicate the occurrence of an AE that may need to be recorded on both the AE page of the eCRF and the Concomitant 
Medication page.  
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page [ADDRESS_1007072] be reported immediately (within 24 hours of discovery) to the Medical Monitor or designee .  Do not delay in the reporting of a suspected SAE in order to obtain 
additional information.  Any additional information, if collected, can be reported to the Sponsor  as a follow -up to the initial report.  SAEs will be reported using the SAE forms 
provided.  Please remember to give details of the patient identification number or other appropriate terminology and ensure the narrative is comprehensive and includes a chronology and assessment of the event.  
 At a minimum, events identified by [CONTACT_737200], 
unexpected, and possibly related to study  drug must be brought to the attention of the 
responsible IRB/IEC.  For EU member States , Bonti  or designee will provide reports of 
suspected unexpected serious adverse reactions  (S[LOCATION_003]Rs ) directly to the IECs , as required by 
[CONTACT_19666].  In all other countries, it is the Investigator ’s responsibility to provide these 
expedited reports to the responsible IRB/IEC.  It is also the Investigator ’s responsibility to 
notify the responsible IRB/IEC regarding an y new and significant safety information.  
 The process for reporting an SAE  or study drug overdose  is as follows:  
 
• Complete an AE eCRF page.  
• Complete an SAE form— this must include th e patient identification number.  
• Complete the narrative, which should be c omprehensive and include a chronological 
descript ion and assessment of the event.  
• Complete the cover sheet.  
• Call the Medical Monitor or designee  for life -threatening or fatal events (see details 
that follow) . 
• Include results of any related laboratory tests  or investigations, histopathologic 
examinations, or consultations with other healthcare professionals that serve to clarify the nature of the event, the cause of the event, or both.  
• Email the cover sheet and the SAE form (within 24  hours of discovery) to the Medical 
Monitor or designee  (see details that follow) . 
 Follow -up information on a previously reported SAE should be processed using a new SAE 
form.  Follow -up information includes additions, deletions, and corrections to the initial 
report.  Previousl y signed, dated, and emailed  forms should not be altered to provide 
follow -up SAE information of any type.  The following must be done when providing follow -
up information:  
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 64 of 93 
 • Mark the box that indicates follow -up information is being provided.  
• Fill out the dates on each page of the form that indicates this is a follow -up report. 
• Restate the event as it appears on the initial report.  If the event has changed, 
indicate, with parentheses, what the event was previously per the example below:  
 SERIOUS ADVERSE EV ENT  Myocardial Infarction  
Diagnosis or Sign/Symptom  (previously chest pain)  
 
Bonti or designee will p rovide the Investigator  with alternative contact [CONTACT_737201].  
 
These events should continue to be reported within 24  hours of discovery, particularly for 
life-threatening or fatal events, and the Investigator  should continue to provide reports to 
the IRB/IEC, as required.  In the event of any SAE (other than death), the patient will be 
instructed to contact [CONTACT_737]  (or Medical Monitor or designee ) using the telephone 
number provided in the ICF .  All subj ects experiencing  an SAE will be seen by [CONTACT_737202].  
 
All SAEs will continue to be followed until the end of the Study  or until such events have 
resolved or the Investigator , in conju nction with the Sponsor , deems them to be chronic or 
stable.  
 SAEs occurring up to 30 days after the study follow up period should be reported if in the judgement  of the Investigator  there is “a  reasonable possibility” that the event may have 
been caused by [CONTACT_77425].   
 
8.5.[ADDRESS_1007073] 2  months prior to the day of dos ing.  All 

IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 65 of 93 
 male subjects with partner(s) of childbearing potential must agree to use dual methods of 
contraception from the day of dosing until [ADDRESS_1007074] through the pregnancy 
term, and report to the Medical Monitor or designee the course of the pregnancy, including 
perinatal or neonatal outcome.  
 
Information on the status of the mother and the child will be forwarded to the Medical 
Monitor or designee using the Pregnancy Notification Follow -up Form.  Any premature 
termination of the pregnancy will also be reported on this form.  
 Although pregnancy occurring in a clinical study is not consider ed to be an SAE, any 
pregnancy complication or elective termination of a pregnancy for me dical reasons will be 
recorded as an AE and will be followed as such.  A spontaneous abortion is considered to be 
an SAE.  
 
8.6 Study Halting Rules  
See Section 4.1.1 . 
 
8.7 Safety Oversight  
The study Data Review Team (DRT) including the Investigator s, Medical Monitor, Study 
Director as well as other ad hoc  representatives as appropriate will regularly monitor all 
aspects of patient safety throughout this study.  The DRT will review all available data  in a 
blinded manner  (may include:  vital signs,  ECGs  clinical laboratory tests, incidence of SAE and 
TEAE ) to assess the safety of each dose level of EB -001 prior to escalating to the next dose 
level.    
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page [ADDRESS_1007075], inspecting the various records of the study (e.g., eCRFs and other pertinent data), 
provided that subject confidentiality is respected.  
 
The study monitor is responsible for inspecting the eCRFs at regular intervals throughout the study to verify the following:  adherence to the protocol;  completeness, accuracy, and 
consistency of the data; and adherence to local regulations on the conduct of clinical research.  The monitor should have access to subject medical records and other study -
related records needed to verify the entries on the eCR Fs.  The Investigator  must agree to 
cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved.  
 In accordance with ICH Good Clinical Practice (GCP) and the Sponsor  audit plans, this study 
may be s elected for an audit.  Inspection of site facilities (e.g., pharmacy, drug storage areas, 
laboratories, etc.) and review of study -related records may occur in order to evaluate the 
trial conduct and compliance with the protocol, ICH GCP , and applicable reg ulatory 
requirements.  
 A separate clinical monitoring plan (CMP) should describe in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. A CMP ordinarily should 
focus on preventing or mitigating important and likely risks, identified by a risk 
assessment, to critical data and processes. The types (e.g., on -site, centralized), 
frequency (e.g., early, for initial assessment and train ing versus throughout the study), 
and extent (e.g., comprehensive (100% data verification) versus targeted or random review of certain data (less than 100% data verification)) of monitoring activities will depend on a range of factors, considered during the risk assessment, including the complexity of the study design, types of study endpoints, clinical complexity of the study population, geography, relative experience of the PI [INVESTIGATOR_737186], 
electronic data capture, relative safety of the  study agent, stage of the study, and 
quantity of data.  
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 67 of 93 
 10 STATISTICAL CONSIDERATIONS  
10.1 Statistical and Analytical Plans  
A formal statistical and analytical plan (SAP) will be completed  prior to database lock and 
unblinding of the study data.  
 
10.[ADDRESS_1007076] deviation, minimum, and maximum.  Categorical variables will be summarized using descriptive statistics of number and percentage of patients in each category.  
 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  
Baseline characteristics and change from baseline (CBL) of Investigator ’s assessment of GL 
severity at maximum using the FWS will be summarized using descriptive statistics, with 
details provided in patient listings.  
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 68 of 93 
  
  
 
 
 
10.4.4  Safety Analyses  
[IP_ADDRESS]  Demographics and Baseline Characteristics  
Demographic and baseline characteristics (medical history, physical examination, prior 
medications) will be summarized us ing descriptive statistics, with details provided in patient 
listings.  
 
[IP_ADDRESS]  Prior and Concomitant Medications  
All prior and concomitant medications will be assigned a generic name [INVESTIGATOR_1238] a drug class based on the World Health Organization (WHO) Dictionary.  Prio r and concomitant 
medications will be listed and summarized by [CONTACT_156276].  
[IP_ADDRESS]  Completion of the Study and Withdrawals  
Withdrawals and the reason for withdrawal (AE(s), protocol non -compliance, lost to 
follow -up, failed to return, did not meet entrance criter ia, voluntary withdrawal, and other 
reasons) will be tabulated.  The number and percentage of subjects who complete the study and who withdraw from the study will be tabulated.  
 
[IP_ADDRESS]  Tolerability Analysis  
Tolerability will be assessed at each dose level of EB -001 /placebo by [CONTACT_737203] 3.  If 
[ADDRESS_1007077] tolerated dose (see Section  4.1.1 ). 
 
[IP_ADDRESS]  Adverse  Events  
Adverse events will be classified into standard terminology using the Medical Dictionary for Regulatory Activities (MedDRA).  Adverse events w ill be listed by [CONTACT_737204] 
(MedDRA -preferred term) , dates and times of onset  and resolution , clinician’s assessment of  
severity, assessment of relatedness to study drug (either related or not related) , and  action 
taken .  Additionally, data may be g rouped for analysis by [CONTACT_737205] 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 69 of 93 
 hierarchy.  The incidence of AEs, the incidence of treatment -related AEs, and the severity of 
AEs will be tabulated  
 
Serious adverse events, treatment -related SAEs (with subsets for SAEs resulting in de ath and 
non-fatal SAEs) and subjects who withdraw due to an AE will be tabulated.  
 
[IP_ADDRESS]  Clinical Laboratory  Tests  
Clinical laboratory test parameters will be listed for individual subjects.  Baseline for clinical 
laboratory parameters will be defined as the la st evaluation before dosing with study 
treatment.  For each parameter, with the exception of urinalysis parameters, summary 
statistics, including mean absolute change from baseline, will be calculated for each measure and summarized; urinalysis results will be listed but not summarized.  In addition, for leukocyte and lymphocyte counts, percentage change from baseline will be tabulated.   
 Each clinical laboratory test will be defined to be “Low”, “Normal”, or “High”, according to the normal reference range  from the clinical laboratory.  The number and percentage of 
subjects who have a shift from within to outside the normal reference range (and vice versa) from baseline to each follow -up visit will be summarized.  
 Each clinical laboratory test will also be  assigned to a grade based on the CTCAE  v4.03  
(CTCAE 2010) .  The number and percentage of subjects who have Grade  2, Grade  3, or 
Grade  4 laboratory value will be summarized.  
 
[IP_ADDRESS]  Vital Signs  
Vital signs results (including BP [systolic and diastolic], pulse rate, and body temperature) will be listed for individual subjects.  Baseline for vital signs measurements will be defined as the last evaluation before dosing with study medication.  Summary statistics, including mean 
chang e from baseline, will be determined for each measure and will be tabulated.   
 Vital signs will be reviewed for notable abnormalities according to the criteria in Table 6, and 
clinically notable vital sign abnormalities will be listed.  The number and percentage of subjects who have a clinically notable vital sign abnormality will be summarized.  
 
Table 6  Criteria for Clinically Notable Vital Sign Abnormalities  
Parameter  High Threshold  Low Th reshold  
Systolic BP  >30 mmHg increase from baseline  >30 mmHg decrease from baseline  
Diastolic BP  >20 mmHg increase from baseline  >20 mmHg decrease from baseline  
Pulse rate  >120 beats/min and an increase in pulse 
rate of ≥15 beats/min from baseline  <40 beats/min and a decrease in pulse 
rate of ≥15 beats/min from baseline  
Body temperature  >39.0°C (= >102.2°F) <35.0°C (= <95.0°F) 
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 70 of 93 
 [IP_ADDRESS]  Electrocardiograms   
ECG intervals/durations (RR, PR, QT, QT cF, and QT cB intervals and QRS duration) and HR will 
be listed for individual subjects.  Baseline for ECG intervals/durations will be defined as the 
mean of the triplicate values recorded on the last evaluation before dosing with study 
medication .  Summary statistics, including mean change from baseline, will be determine d 
for each measure and will be tabulated.   
 
Electrocardiographic intervals and durations will be reviewed for notable abnormalities 
according to the criteria in Table 7, and clinically notable abnormalities will b e listed.  In 
addition, other ECG findings considered to be clinically significant (for example, rhythm 
disturbances, conduction abnormalities, T  wave/ST  segment abnormalities, etc.) will also be 
listed.  The number and percentage of subjects who have a cl inically notable ECG interval 
abnormality or other clinically significant ECG finding will be summarized.   
 
Table 7  Criteria for Clinically Notable ECG Interval Abnormalities  
Interval/Duration  High Threshold  Low Threshold  
PR inte rval PR interval ≥220 msec  PR interval ≤120 msec  
QRS duration  QRS duration ≥120 msec and an increase in QRS 
duration of ≥20 msec from baseline  – 
QT interval  QT interval >500 msec  – 
QT c intervals1 Males:  QT c interval ≥450 msec and an increase in 
QT c interval of ≥ 60 msec from baseline  
or QT c interval >500 msec  – Females:  QT c interval ≥470 msec and an increase in 
QT c interval of ≥ 60 msec from baseline  
or QT c interval >500 msec  
 1 Fridericia’s and Bazett’s corrections (QT cF and QT cB, respectively) 
 
[IP_ADDRESS]  Phys ical and Focused Neurological Examination s 
Findings of physical and focused neurological examinations  will be listed for individual 
subjects and summarized.  
 
For the evaluation of SOT terms, the criteria for Grading are:  
 
• Grade 1 (Mild): Asymptomatic or mi ld symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
• Grade 2 (Moderate): Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL).  Instrumental ADL refer 
to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
• Grade 3 (Severe or medically significant but not immediately life -threatening): 
Hospi[INVESTIGATOR_3111]; disabling; limiting  self-
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 71 of 93 
 care ADL.  Self -care ADL refer to bathing, dressing and undressing, feeding self, using 
the toilet, taking medications, and not bedridden  
• Grade 4 (Life -threatening consequences): Urgent intervention indicated.  
• Grade 5 (Death related to AE).  
 
[IP_ADDRESS]   Urine Drug Test  
Results of urine drug test will be listed for individual subjects .  Each test will be defined to be 
“negative” or “positive”, according to the normal reference range from the clinical 
laboratory.  The number and percentage of subjects who are “positive” or “negative” in each 
visit will be summarized.  
 
[IP_ADDRESS]   Pregnancy Test  
Results of pregnancy test will be listed for individual subjects .  Each test will be defined to be 
“negative” or “positi ve”, according to the normal reference range from the clinical 
laboratory.  The number and percentage of subjects who are “positive” or “negative” in each visit will be summarized.  
 
10.4.[ADDRESS_1007078] human study to evaluate the safety and efficacy of EB-001, and therefore 
there are no data on which to base sample sizes.  However, a sample size o f 5 subjects per 

IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 72 of 93 
 cohort (n  = 5 EB-001, n  = 1 placebo) is considered to provide sufficient initial information on 
the estimation of the safety and tolerability of E B-001.   
 
With 5 subjects receiving each dose level of EB -001 per cohort, an AE that occurs w ith a true 
frequency of 50% will be detectable with 96.9% probability within a given cohort.  Combined 
across cohorts, with 35  subjects receiving EB-001, an AE that occurs with a true frequency of 
10% will be detectable with greater than 97.5 % probability.   The probability of detecting AEs 
is shown in Table 8: 
 
Table [ADDRESS_1007079] 
1 Event with 35 Subjects  
0.01  4.9% 29.7 % 
0.1 41.0% 97.5 % 
0.2 67.2 % >99%  
0.5 96.9 % >99%  
 
10.6 Measures to Minimize Bias  
10.6.1  Enrollment/ Randomization/ Blinding Procedures  
Subjects who meet the enrollment criteria will be enrolled into sequential cohorts. Patients 
are considered to be randomly assigned to the study when they are assigned to receive 
either EB -001 or placebo.   Within each cohort, subjects will be randomly allocated to receive 
eithe r EB-001 or placebo in a 5:1 ratio .  The dosage level of EB -001 will not be randomized . 
 The study will be conducted in a double -blinded manner.  Study drugs between EB -001 and 
the placebo vials will be identical in appearance .  Study site personnel who pr epare the 
study drug will not be involved in safety and efficacy assessment.  
 There  will be an unblinded independent dispenser who will prepare and dispense EB -001 or 
placebo for administration in a blinded manner to subjects.  The Investigator  and site 
personnel, study subjects, and Sponsor  personnel will be aware of the EB -001 dose level in 
each dose cohort; however, except for a limited number of Sponsor  staff (see below), they 
will be unaware of whether subjects are receiving EB -001 or placebo until the  study is 
formally unblinded.  
 
[IP_ADDRESS]  Subject Numbering  
Patients who have signed the ICF to begin screening procedures will be entered into the 
electronic data capture (EDC) system.   The site will assign a [ADDRESS_1007080] of a 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 73 of 93 
 3-digit original site number followed by a 3 -digit screening number.   The patient will keep 
the same number throughout the study.  Upon randomization, a unique 4 -digit study -
specific random ization number will be assigned by [CONTACT_488277] 
(IVRS) or Interactive Web Response System (IWRS) system.    
 
In the rare circumstance, where a patient is randomly assigned to treatment but does not 
receive the study drug, the study c oordinator/research nurse must immediately inform the 
IVRS or IWRS that the study drug was not administered.  
 
10.6.2  Evaluation of Success of Blinding  
[IP_ADDRESS]  Blinding at the Study Site  
Study treatment group information (active drug vs placebo) will remain blinded to the  
subject and also to all blinded members of the study team at the study site. There will be an 
unblinded independent dispenser who will prepare and dispense EB -[ADDRESS_1007081] access to it (including all routine laboratory tests, imaging, and AEs) must not discuss any unblinded information or results with the site 
personnel responsible for blinded study assessments.  
 
[IP_ADDRESS]  Blinding of Sponsor  Personnel  
During this study, staff of Bonti and designee will be blinded to treatment allocation, except as described in this section.  The periodic DRT reviews will be performed in a blinded manner unless the data warrant unblinding due to safety concerns.
  It is assumed that the 
need to unblind a study subject’s treatment assignment will occur in t he setting of a n SAE, 
and therefore, all procedures for the reporting of a SAE must be followed (see Section  8.5.1 ). 
 Procedures for emergency unblinding are described in Section 10.6.[ADDRESS_1007082] premature access to the study subjects’ treatment assignments.  Any 
personnel from Bonti and designee who become unblinded to study safety and efficacy data 
will be documented and no longer participate in day -to-day management of the study.  
 
10.6.3  Breaking the Study Blind/Participant Code  
An Investigator  at a site may break the blind  in the event of an immediate medical 
emergenc y, where knowledge of the study subject’s treatment assignment (EB -001 or 
placebo) must be known in order to facilitate appropriate emergency medical treatment.  In 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page [ADDRESS_1007083]’s treatment identity in order to obtain concurrence 
that unblinding a study subject’s treatment assignment is necessary.  If circumstances 
preclude contact[CONTACT_737206] , each instance of unblinding must be 
reported to Sponsor  within 24 hours.  The Medical Monitor or designee may break the blind 
internally in the event of SAE (s), which require expedited reporting to regulatory 
authorities.  Any other requests to reveal a subject’s treatment identity mus t be requested 
of, and approved by  [CONTACT_177006] .  If a study subject’s treatment 
identity is unblinded by [CONTACT_3452], the unblinding must be reported to Bonti  and 
documented on the eCRF as a deviation.   If a subject’s treatment identity is unblinded, the 
subject will be withdrawn from the study and will complete the Early Termination 
procedures describe in Section 5.4. 
 
In an emergency situation in which the Investigator  believes that the i dentity of a study 
subject’s treatment assignment is necessary to treat the subject , the study subject’s 
treatment assignment may be obtained from the 24 -hour IVRS/IWRS.  Details of the process 
to be followed and the telephone number are provided in the study manual( s) provided to 
the site .  In the event that the IVRS/IWRS is used to perform a code break, Bonti  or designee 
will be notified immediately by [CONTACT_21926]/IWRS using an automated notification.   
 
The Investigator  or designee is responsible for ensuring that the instructions on how to 
perform a code break are stored safely, that their location is known, and that access is 
readily available to the relevant staff in case of an emergency.  
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 75 of 93 
 11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS 
Each participating site will maintain appropriate medical and research records for this trial, 
in compliance with ICH E6 and regulatory and institutional requirements for the protection of confidentiality of participants.  
 The clinical sit e participating in this study  are required to submit clinical data for each 
enrolled subject via an EDC system, using an eCRF.   Site personnel will be trained on the EDC 
system before receiving access to the system.  The Sponsor  or designee is responsible for 
maintaining a record of all system users.  The participants of the study will not be identified by [CONTACT_737207]  (see Section 13.4 ). 
 All clinical information requested in this protocol will be recorded on the eCRF provided by 
[CONTACT_2024]  (or via other data collection methods, e.g. electronic laboratory data transfer).  The 
principal Investigator  [INVESTIGATOR_737187], verifying them for accuracy, and 
approving them via an electr onic signature.  Copi[INVESTIGATOR_395823], saved to disk in 
.pdf format, will be sent to the Investigator ’s site at the completion of the study.  
 Additional s ource data  may  include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and 
office charts,  laboratory notes, memoranda, participant’s memory aids or evaluation 
checklists, pharmacy dispensing records, recorded audio tapes of counseling sessions, recorded data from automated instruments, copi[INVESTIGATOR_400597] b eing accurate and complete, photographic negatives, and participant files 
and records kept at the pharmacy, at the laboratories, and medico -technical departments 
involved in the clinical trial.   
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 76 of 93 
 12 QUALITY ASSURANCE  AND QUALITY CONTROL  
See Section 9. 
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 77 of 93 
 13 ETHICS/ PROTECTION  OF HUMAN SUBJECTS  
13.[ADDRESS_1007084]  
The Investigator  will ensure that this study is conducted in full conformity with Regulations 
for the Protection of Human Subjects of Research codified in 45 Cod e of Federal Regulations  
(CFR)  Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  
 
13.[ADDRESS_1007085]  
The protocol, informed consent form(s), recruitment materials, and all participant materials 
will be submitted to the IRB for review and approval.  Written a pproval of both the protocol 
and the consent form must be obtained before any participant is enrolled.   Any amendment 
to the protocol will require review and approval by [CONTACT_3484].  All chan ges to the consent form will be IRB approved; a 
determination will be made regarding whether previously consented participants need to be re-consented.
 
 
13.[ADDRESS_1007086]’s agreement to participate.  Among other things,  the Investigator  will fully 
explain in layman’s terms the nature of the study, along with the aims, methods, potential risks, and any discomfort participation may entail.  The subject must sign and date the ICF before any study -related procedures are perf ormed.  The original and any amended signed 
and dated ICF(s) must be retained in the subject’s file at the study site and a copy must be 
given to the subject.  
 
13.[ADDRESS_1007087]’s anonymity is maintained as described 
below.  On the eCRFs or other documents submitted to the Sponsor , subjects must be 
identified by [CONTACT_737208], date of birth, and a Subject Identification Number.  
Documents that are not for submission to the Spons or (e.g., signed ICFs) should be kept in 
strict confidence by [CONTACT_737209] 
E6 Guidelines  (FDA 2015 ). Participant confidentiality is strictly held in trust by [CONTACT_397890] s, their staff, and the Sponsor (s) and their agents. This 
confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants.  Therefore, the study protocol, 
documentation, data, and all other information generated will be held in strict confidence.  
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page [ADDRESS_1007088]’s original medical 
records for verification of study -related procedures and data.  Direct access include s 
examining, analyzing, verifying, and reproducing any records and reports that are needed for 
the evaluation of the study.  The Investigator  is obligated to inform the subject in the ICF that 
the above named representatives may review study -related record s from subjects.
 
 
13.4.1  Research Use of Stored Human Samples or Data  
Samples and data collected under this protocol may be used to study the safety and efficacy of EB -001.  All data and materials created from the samples will be the property of the 
Sponsor .  Samples collected will be stored in either the laboratory of the Sponsor  or the 
laboratory of a company contracted to work with the Sponsor  with a proper tracking system .  
Access to study samples will be limited to laboratory personnel working for the Sponsor  or 
contracted to the Sponsor , who are authorized to perform analyses.   
 Samples collected may be stored for up to 10  years after the end of the study (the end of the 
study occurs when a final study report is written).    
 
13.5 Future Use of Stored Specimens  
Additional tests may be conducted in case there are substances discovered about which 
we are not currently aware that might help us better understand or develop treatments for glabellar line, and/or for safety issues that may arise in the future .
 
 During the  conduct of the study, an individual participant can choose to withdraw 
consent to have biological specimens stored for future research. However, withdrawal of consent with regard to biosample storage will not be possible after the study is completed.   
 
13.[ADDRESS_1007089].  The Investigator  should notify the IRB in writing of 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 79 of 93 
 the trial’s completion or early termination and send a copy of the notification to the 
Sponsor . 
 
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page [ADDRESS_1007090] KEEPI[INVESTIGATOR_1645]  
14.1 Data Collection and Managem ent Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site under the 
supervision of the site Investigator .  The Investigator  is responsible for ensuring the 
accuracy, completeness, legibility, and timeliness of the d ata reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014].  When 
making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 
Data reported in the eCRF derived from source documents should be consistent with the 
source documents or the discrepancies should be explained and maintained in the 
participant’s official study record.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) 
and clinical laboratory data will be entered into Axiom Fusion , a [ADDRESS_1007091] be maintained that includes the signed ICF and the Investigator ’s copi[INVESTIGATOR_737188].  The Investigator  must ensure the 
reliability and availability of source documents from which the  information on the eCRF was 
derived.  
 
Investigator s are required to maintain all study documentation, including copi[INVESTIGATOR_1495], 
ICFs, and adequate records for the receipt and disposition of all study medications, for a 
period of [ADDRESS_1007092] identity information will be maintained for 15  years unless applicable law or 
regulation requires a longer period.  
IND 130880  18 November  2016 
 
 
 Confidential / Trade Secret  Page 81 of 93 
  
14.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol  or GCP 
requirements. The non -compliance may be either on the part of the participant, the 
Investigator , or the study site staff.  As a result of deviations, corrective actions may  be 
developed by [CONTACT_3483].  
 
These practices are consistent with I CH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_1007093] be addressed in study source documents  and transcribed into the eCRF  
(as applicable) .  Protocol deviations must be sent to the local IRB per their guidelines.  The 
site Investigator  and study staff are  responsible for knowing and adhering to their IRB 
requirements.   
 
14.4 Publication and Data Sharing Policy  
All pub lication and authorship rights are delineated in the Clinical Study Agreement.  
 